A
53.92
-0.11 (-0.20%)
| Previous Close | 54.03 |
| Open | 54.10 |
| Volume | 4,370,249 |
| Avg. Volume (3M) | 1,599,824 |
| Market Cap | 4,298,372,608 |
| Price / Book | 4.04 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -3.75 |
| Total Debt/Equity (MRQ) | 3.34% |
| Current Ratio (MRQ) | 16.80 |
| Operating Cash Flow (TTM) | -262.63 M |
| Levered Free Cash Flow (TTM) | -177.47 M |
| Return on Assets (TTM) | -18.52% |
| Return on Equity (TTM) | -27.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Akero Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
1.8
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.75 |
|
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.39% |
| % Held by Institutions | 109.29% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 78.00 (Citigroup, 44.66%) | Buy |
| Median | 71.00 (31.68%) | |
| Low | 64.00 (B of A Securities, 18.69%) | Buy |
| Average | 71.00 (31.68%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 43.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 27 May 2025 | 64.00 (18.69%) | Buy | 46.00 |
| Citigroup | 13 May 2025 | 78.00 (44.66%) | Buy | 40.01 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |